Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab

Case Reports in Oncology

Volumn 5, Issue 3, 2012, Pages 676-681

  Gasent Blesa, Joan Manel ^a   Blasco Mollá, Sara ^a   Fonfría Esparcia, María ^a   Sempere Ortells, JoséMiguel ^b   Peris Godoy, Miguel ^a   Munilla Das, Adrian ^a   Mancheño Magan, Balbino ^b   Provencio Pulla, Mariano ^c   Sanchez, Jose Luis ^d   Bautista Laforga Canales, Juan ^a   Alberola Candel, Vicente ^a  

^a Hospital de Denia   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

Bevacizumab; Cetuximab; Durable remission; Glioma

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IRINOTECAN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; TEMOZOLOMIDE;

ACNE; ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN STEM GLIOMA; BRAIN STEM TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CONTRAST ENHANCEMENT; DERMATITIS; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 84873166281     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000341852     Document Type: Article

References (21)

1. Salmaggi A, Boiardi A, Gelati M, et al: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006;54:850-860.
2. Freeman CR, Perilongo G: Chemotherapy for brain stem gliomas. Childs Nerv Syst 1999;15:545-553.
3. Shuper A, Kornreich L, Loven D, Michowitz S, Schwartz M, Cohen IJ: Diffuse brain stem gliomas. Are we improving outcome? Childs Nerv Syst 1998;14:578-581.
4. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunet-Mentigny M, Philip T: High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 1997;39:376-379.
5. Allen JC, Siffert J: Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 1996;24:98-102.
6. Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, Kuehl J: Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 2002;87:945-949.
7. Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
8. Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
9. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2008;26:91s (abstr 2010b).
10. Galli R, Binda E, Orfaneli U: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7012.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
12. Singh SK, Clarke ID, Hide T, Dirks PB: Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-7273.
13. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nature 2005;5:275-284.
14. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ: Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997;89:3104-3112.
15. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
16. Hope KJ, Jin L, Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-743.
17. Yao XH, Ping YF, Chen JH, et al: Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 2008;215:369-376.
18. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-3024.
19. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviate edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
20. Stupp R, Mason WP, Van der Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
21. Galli R, Gritti A, Bonfanti L, et al: Neuronal Stem Cells. Circulation Research 2003;92:598.